Payment overview · 2025
General Payments
$1,686.88
95 reported records · 27 companies
Healthcare provider profile · identity verified
Rylan Chan, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MERIDIAN, ID · NPI 1306874623
Verified facts
What the public records show
CMS Open Payments records show Rylan Chan, PAC received $1,686.88 in general payments during 2025 across 95 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta, Veozah.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.35 | 12.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.04 | 10.8% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $179.08 | 10.6% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $146.33 | 8.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.23 | 8.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.56 | 5.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $79.20 | 4.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.88 | 3.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.64 | 3.5% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $56.24 | 3.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.03 | 3.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.84 | 2.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.98 | 2.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.09 | 2.5% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $34.30 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.13 | 2.0% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $33.37 | 2.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.50 | 1.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.21 | 1.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.91 | 1.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.32 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.41 | 1.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.35 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.87 | 1.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.36 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.11 | 0.8% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $13.55 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,686.88 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $151.72 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $141.84 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.19 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.32 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $106.26 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.19 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.77 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.04 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.74 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $79.20 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.29 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.89 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.64 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.47 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.76 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.76 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $56.24 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.03 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.71 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.84 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.98 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.09 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.19 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.56 | 5 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $34.30 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $34.13 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $29.27 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 119 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 46 |
| Lisinopril | Lisinopril | 176 | 48 |
| Losartan Potassium | Losartan Potassium | 176 | 46 |
| Omeprazole | Omeprazole | 170 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 42 |
| Gabapentin | Gabapentin | 130 | 28 |
| Farxiga | Dapagliflozin Propanediol | 119 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 26 |
| Metformin Hcl | Metformin Hcl | 90 | 22 |
| Trazodone Hcl | Trazodone Hcl | 89 | 27 |
| Eliquis | Apixaban | 83 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 16 |
| Sertraline Hcl | Sertraline Hcl | 66 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 18 |
| Potassium Chloride | Potassium Chloride | 64 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 23 |
| Simvastatin | Simvastatin | 58 | 13 |
| Celecoxib | Celecoxib | 54 | 20 |
| Mounjaro | Tirzepatide | 54 | 12 |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Ozempic | Semaglutide | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 12 |
| Furosemide | Furosemide | 44 | 14 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 11 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Meloxicam | Meloxicam | 26 | 13 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Carvedilol | Carvedilol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 14 |
| Finasteride | Finasteride | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lamotrigine Odt | Lamotrigine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,686.88 · 95 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, General - Pain Management, INCEPTIV, JARDIANCE, Jornay PM, Kerendia, Korlym, LEQVIO, MAKO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, PROLIA, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, SX-ONE MICROKNIFE, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error